CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0092 (clinicaltrials.gov NCT No: NCT00903760)
Title:A randomized study of decitabine alternating with clofarabine versus decitabine until failure in patients with higher risk MDS
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Clofarabine; Decitabine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if sequential
administration of decitabine and clofarabine can help to control MDS better
than decitabine alone. The safety of this drug combination will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Clofarabine
Decitabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Patients may require hospitalizations of up to 5 days for clofarabine.
Hospitalization is not mandatory and outpatient administration of chemothearpy
is permitted.
Supported By:N/A
Return Visit:Patients will return to MD Anderson Cancer Center prior to each course.
Home Care:Therapy will be administered either at MDACC or outside MDACC as allowed and
approved by the principal investigator. Patients may be followed locally in
between therapies for blood work and supportive care.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
Dept:Leukemia
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults